Advertisement

Topics

$FOMX Positive Topline Results from Phase 3 Program Evaluating FMX103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea. CC 8:30AM https://finance.yahoo.com/news/foamix-announces-positive-topline-results-110000340.html …

06:11 EST 7 Nov 2018 | Odi Bruckman

Positive Topline Results from Phase 3 Program Evaluating FMX103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea. CC 8:30AM https://finance.yahoo.com/news/foamix-announces-positive-topline-results-110000340.html …

Original Article: $FOMX Positive Topline Results from Phase 3 Program Evaluating FMX103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea. CC 8:30AM https://finance.yahoo.com/news/foamix-announces-positive-topline-results-110000340.html …

NEXT ARTICLE

More From BioPortfolio on "$FOMX Positive Topline Results from Phase 3 Program Evaluating FMX103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea. CC 8:30AM https://finance.yahoo.com/news/foamix-announces-positive-topline-results-110000340.html …"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Mirvaso (brimonidine)
MIRVASO® (BRIMONIDINE) TOPICAL GEL, 0.33%* IS THE FIRST & ONLY FDA-APPROVED TREATMENT DEVELOPED AND INDICATED FOR PERSISTENT FACIAL REDNESS OF ROSACEA Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for th...